RxDoctor Payments Data

Marc Siegel, MD

Infectious Disease · Washington, DCNPI 1306866140

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (50.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Intuitive Surgical at 50.3% of the total.

$5,258in general payments, 2019–2025

Across 42 payments — averaging $125.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Gilead$2K
  • Viiv Healthcare Company$222
  • Shionogi Inc$145
  • Janssen Products, LP$65
  • Ferring Pharmaceuticals Inc.$55
  • plus $54 from 2 others
$796,315in research payments, 2019–2025

Across 44 payments — averaging $18,098 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$698K
  • GSK$36K
  • Viiv Healthcare Company$35K
  • Gilead$28K

What the payments were for

  • Consulting fees$1,75033%
  • Travel & lodging$2,64350%
  • Food & beverage$65412%
  • Education$2104%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,258 in reported general payments places this provider in the 80th percentile of 74 infectious disease providers in District of Columbia.

See all infectious disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$81,228
Medicare patients
239
Services billed
1,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala235$1,117,035
JulucaDolutegravir/Rilpivirine129$502,732
DovatoDolutegravir Sodium/Lamivudine92$297,372
RukobiaFostemsavir Tromethamine19$165,850
TivicayDolutegravir Sodium39$101,617
CabenuvaCabotegravir/Rilpivirine11$78,423
PrezcobixDarunavir/Cobicistat28$72,124
TriumeqAbacavir/Dolutegravir/Lamivudi12$63,810
PifeltroDoravirine17$38,115
DelstrigoDoravirine/Lamivu/Tenofov Diso11$29,009
DescovyEmtricitabine/Tenofov Alafenam12$25,214
ValacyclovirValacyclovir Hcl29$1,676
Vancomycin Hcl16$1,393
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$528
Doxycycline Hyclate17$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Rukobia, Tivicay, Cabenuva$222$1,209,804302 claims
GileadBiktarvy, Descovy$2,074$1,142,249247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 74 infectious disease providers in District of Columbia.

Other infectious disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →